Remission rates for ovarian cancer patients remained stable before and after the COVID-19 pandemic, despite treatment delays and protocol changes. The study involved 748 patients, with no significant ...

The study covered in this summary was published on ssrn.com as a preprint and has not yet been peer reviewed. Cytarabine plus an anthracycline has been the standard AML induction regimen for decades, ...

The early RAINIER data showed a 79% CR/CRi rate in evaluable frontline TP53-mutated AML patients, comparing favorably with a published 41% composite remission benchmark for venetoclax plus azacitidine ...

After a patient has undergone treatment for cancer, they may be told that the disease is either in "remission" or that they have been "cured." But there's a distinction between these terms. So what ...

Please provide your email address to receive an email when new articles are posted on . Treatment with CTX130, a novel chimeric antigen receptor T-cell therapy, led to disease control in more than ...

HOUSTON, June 30, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced positive preliminary unblinded efficacy results from the first 45 ...

SEATTLE, WA / ACCESSWIRE / November 3, 2020 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its ...

Researchers at the University of Cincinnati Gardner Neuroscience Institute's Brain Tumor Center have been confirmed as the first in the world to achieve complete remission of a rare pituitary cancer ...

IN8bio, Inc. announced that 100% of acute myeloid leukemia (AML) patients treated with its allogeneic gamma-delta T cell therapy, INB-100, remain in complete remission (CR) with a median follow-up of ...

As soon as I entered complete remission for multiple myeloma, I felt a glimmer of hope. The word "remission" carries a sense of hope and relief, like the first ray of sunshine breaking through the ...